(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 September 2011 (09.09.2011)

PCT

(10) International Publication Number
WO 2011/106885 A1

(51) International Patent Classification:
C07K 14/47 (2006.01) *A61P 37/04* (2006.01)
A61K 39/00 (2006.01) *C07K 16/18* (2006.01)
A61K 39/395 (2006.01) *C12N 15/13* (2006.01)
A61P 25/28 (2006.01) *G01N 33/53* (2006.01)

(21) International Application Number:
PCT/CA2011/000238

(22) International Filing Date:
3 March 2011 (03.03.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/310,167 3 March 2010 (03.03.2010) US

(71) Applicant *(for all designated States except US)*: **THE UNIVERSITY OF BRITISH COLUMBIA** [CA/CA]; 103 - 6190 Agronomy Road, Vancouver, British Columbia V6T 1Z3 (CA).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **CASHMAN, Neil R.** [CA/CA]; 3793 West King Edward Ave, Vancouver, British Columbia V6S 1M8 (CA).

(74) Agents: **PISKO, J. Erin** et al.; Borden Ladner Gervais LLP, 1200 Waterfront Centre, 200 Burrard Street, P.O. Box 48600, Vancouver, British Columbia V7X 1T2 (CA).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

[Continued on next page]

(54) Title: OLIGOMER-SPECIFIC AMYLOID BETA EPITOPE AND ANTIBODIES




Fig. 4

(57) Abstract: A novel constrained peptide epitope derived from Aβ, wherein the eptitope comprises the amino acid sequence SNK, related antibody compositions and methods of use. An isolated antibody that specifically binds to a cyclic peptide comprising the conformational epitope which comprises the amino acid sequence SNK and corresponding to a solvent-exposed, antibody accessible knuckle region of oligomeric Aβ is described. An antigenic peptide comprising an epitope having a constrained cyclic configuration, which comprises the amino acid seqeuence SNK and corresponding to a solvent-exposed, antibody accessible knuckle region of oligomeric Aβ is also described. Methods of treating, preventing and diagnosing Alzheimer's disease are also described.

WO 2011/106885 A1

GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*